Globally, bladder cancer affects nearly 3 million people worldwide and 430,000 new cases occur each year. In case of early detected cancer, the 5-year survival rate is greater than 95% whereas for advanced cancers, it drops to 5%. It is therefore essential to detect bladder cancer early in order to optimize patient management, improve their survival rate and reduce the costs of care for health systems. And yet there is no satisfactory solution on the market. VitaDX is a young innovative company developing an early diagnosis solution for bladder cancer using fluorescence imaging, image processing and artificial intelligence from a simple urine sample.